Cabaletta Bio, Inc. (CABA) has a negative trailing P/E of -1.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 3.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -51.78%, forward earnings yield 30.67%.
Criteria proven by this page:
Overall SharesGrow Score: 49/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -961.4 | 0.00 | -965.22 | 0.00 | - |
| 2018 | -11.9 | 0.00 | -13.58 | 0.00 | - |
| 2019 | -3.4 | -0.01 | 0.42 | 0.00 | 17.36% |
| 2020 | -8.7 | 0.13 | 2.64 | 0.00 | - |
| 2021 | -2.1 | -0.08 | 0.83 | 0.00 | - |
| 2022 | -5.1 | -9.22 | 2.60 | 0.00 | - |
| 2023 | -13.7 | 1.55 | 3.94 | 0.00 | - |
| 2024 | -1.0 | -0.02 | 0.74 | 0.00 | - |
| 2025 | -1.3 | 0.04 | 2.00 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.01 | $0.00 | $-250K | - |
| 2018 | $-0.84 | $0.00 | $-12.2M | - |
| 2019 | $-4.07 | $0.00 | $-16.94M | - |
| 2020 | $-1.44 | $0.00 | $-33.34M | - |
| 2021 | $-1.80 | $0.00 | $-46.29M | - |
| 2022 | $-1.81 | $0.00 | $-52.98M | - |
| 2023 | $-1.65 | $0.00 | $-67.68M | - |
| 2024 | $-2.34 | $0.00 | $-115.86M | - |
| 2025 | $-1.64 | $0.00 | $-167.86M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.61 | $-2.00 – $-1.07 | $2.5M | $2.5M – $2.5M | 5 |
| 2027 | $-1.55 | $-1.75 – $-1.34 | $712.59K | $712.59K – $712.59K | 4 |
| 2028 | $-1.52 | $-2.99 – $-0.74 | $81.26M | $81.26M – $81.26M | 7 |
| 2029 | $-0.76 | $-0.76 – $-0.76 | $379.72M | $379.72M – $379.72M | 2 |
| 2030 | $0.98 | $0.98 – $0.98 | $810.88M | $810.88M – $810.88M | 5 |
